OncoImmunity AS has been acquired by renowned Japanese IT and network company, NEC Corporate. OncoImmunity AS develops software that identifies neoantigen targets for truly personalized cancer vaccines, cell therapies and optimal patient selection for cancer immunotherapy clinical trials.
GJE provided OncoImmunity AS with IP-related due diligence support during the acquisition and continues to manage the company’s patent portfolio. The GJE team is led by partner Matt Hoyles.
To read the full press release, please follow this link.
Related resources
Managing a Trade Mark Portfolio – Supporting Efficiency and Enhancing Growth: Part 1
For mature businesses with extensive IP portfolios, having a clear and signposted IP strategy in place saves money...
Digital therapeutics: patent strategy in Europe
The issue of chronic disease is imposing a mounting burden on healthcare systems around the world and is...
Navigating product-by-process claims at the European Patent Office
Inventions in the field of chemistry often relate to the discovery of a new product that has been...